Medicine
Krazati 200 mg tablet
Krazati 200 mg tablet is a prescription medicine containing Adagrasib for oral use, marketed by Mirati Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store tablets at room temperature, 20°C to 25°C (68°F to 77°F). Temperature…
Key facts
- Active ingredient (INN)
- Adagrasib
- Brand
- Krazati
- Strength
- 200 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Mirati Therapeutics
- Manufacturer
- Mirati Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store tablets at room temperature, 20°C to 25°C (68°F to 77°F). Temperature excursions between 15°C and 30°C (59°F to 86°F) are permitted.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XX77 Adagrasib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 December 2022
- Identifiers
- RxCUI 2625917, 2625923DailyMed set ID 0b8bf078-34c2-4f45-9012-38a8ac082b01NDC 80739-812Application NDA216340
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 120 tablet, coated in 1 bottle | 80739-812-12 | Mirati Therapeutics | 12 December 2022 |
| 1 bottle in 1 carton / 180 tablet, coated in 1 bottle | 80739-812-18 | Mirati Therapeutics | 12 December 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Adagrasib is a prescription medicine indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test,, among other approved uses. MedsAcross supplies Adagrasib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AdagrasibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- KRAZATI prescribing information (Mirati Therapeutics) · U.S. National Library of Medicine, DailyMed
- Krazati: European public assessment report (EPAR) · European Medicines Agency
Need Krazati 200 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.